为您找到"
cb668
"相关结果约100,000,000个
Background Tumors evade destruction by the immune system through multiple mechanisms including altering metabolism in the tumor microenvironment. Metabolic control of immune responses occurs through depletion of essential nutrients or accumulation of toxic metabolites that impair immune cell function and promote tumor growth. The secreted enzyme interleukin 4 (IL-4)-induced gene 1 (IL4I1) is ...
CB-668 is a potent, selective, small-molecule, oral inhibitor of IL4I1, an amino acid oxidase that inhibits anti-tumor immunity and promotes tumorgrowth. IL4I1 regulates several aspects of adaptive immunity, including inhibition of cytotoxic T cells through its production of both hydrogen peroxide and activators of the aryl hydrocarbon receptor. CB-668 increases pro-inflammatory gene ...
Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that new preclinical data for the company's novel IL4I1 inhibitor CB-668 will be presented at the Society for Immunotherapy of Cancer Virtual Annual Meeting 2020.
Single Cell Analysis Identifies Immune Marker IL4I1 As Critical for Leukemogenesis and Immunity (ASH 2022) - "Finally, we tested IL4I1 expression in response to Fedratinib, a JAK2 inhibitor, and showed that IL4I1 expression was decreased in responders (R) vs nonresponders (NR) (Fig. 2F). We conclude that IL4I1 is a rational immune therapeutic target for AML and testing of IL4I1 Inhibitor CB ...
CB 668 was a small molecule inhibitor of the interleukin 4 induced gene 1 (IL4I1), being developed by Calithera Biosciences, for the treatment of cancer. IL4I1
CB-668Table of Contents Navigate through drug information Drug Information Overview Clinical Information Indication Associated Conditions Clinical Trials Approved Products FDA Products (US) EMA Products (EU) HSA Products (SG) NMPA Products (CN) PPB Products (HK) TGA Products (AU) Related News
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the
705 Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)
Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting IL4I1 inhibitor shows immune-mediated anti-tumor activity November ...
LARVOL VERI predictive biomarker news, CB-668Finally, we tested IL4I1 expression in response to Fedratinib, a JAK2 inhibitor, and showed that IL4I1 expression was decreased in responders (R) vs nonresponders (NR) (Fig. 2F). We conclude that IL4I1 is a rational immune therapeutic target for AML and testing of IL4I1 Inhibitor CB-668 through a collaboration with Calithera is underway.